Oxford BioDynamics Plc (OBD.L)
| Previous close | 11.50 |
| Open | 11.95 |
| Bid | 11.05 x 0 |
| Ask | 12.95 x 0 |
| Day's range | 11.60 - 12.50 |
| 52-week range | 10.98 - 53.60 |
| Volume | |
| Avg. volume | 120,613 |
| Market cap | 12.042M |
| Beta (5Y monthly) | 1.18 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.20 |
| Earnings date | 28 Jun 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 175.00 |
- Business Wire
Oxford BioDynamics’s Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) Now Available in the UK
OXFORD, England, June 21, 2022--Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch® 3D genomics platform, has announced that its flagship Checkpoint inhibitor Response Test (CiRT) clinical blood test is now available to private physicians considering ICI therapy for their patients in the UK.
- Business Wire
Oxford BioDynamics Announces US Launch of Its Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) for Oncology
OXFORD, England, February 25, 2022--Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on its EpiSwitch 3D genomics platform, has announced the successful clinical validation and US launch of its Checkpoint Inhibitor Response Test (EpiSwitch® CiRT).
- Simply Wall St.
Is Oxford BioDynamics (LON:OBD) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
